Latest Share Chat

IN BRIEF: Immupharma Still Awaiting FDA Reply For Lupuzor Submission

Fri, 11th Sep 2020 14:09

Immupharma PLC - pharmaceutical company - Licensing partner Avion Pharmaceuticals has confirmed that while the US Food & Drug Administration review period of 45 days has now passed, its submission for a Special Protocol Assessment for its forthcoming international Phase III trial of its lupus treatment Lupuzor is still under review due to current workload of the regulatory body. Application was submitted in July.

Current stock price: 12.60 pence

Year-to-date change: down 21%

By Ife Taiwo; ifetaiwo@alliancenews.com

Related Shares

More News

2 Apr 2024 12:52

Immupharma jumps amid new IP strategy for P140 technology platform

(Alliance News) - Immupharma PLC on Tuesday announced a new intellectual property strategy to significantly enhance the patent life and commercial val...

25 Mar 2024 12:20

Incanthera says first order from skincare deal doubles

(Alliance News) - ImmuPharma PLC on Monday noted updates on Incanthera PLC's commercial skincare deal with Marionnaud, which was first announced in De...

25 Mar 2024 12:09

LONDON MARKET MIDDAY: Stocks make tepid start to new week

(Alliance News) - Stock prices in London were down at midday on Monday, giving back some gains from last week, when equities were boosted by central b...

25 Mar 2024 10:55

AIM WINNERS & LOSERS: ImmuPharma order doubles; Aeorema swings to loss

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

6 Mar 2024 13:05

EARNINGS AND TRADING: Challenger signs farm-out; Ricardo revenue up

(Alliance News) - The following is a round-up of earnings and trading updates of London-listed companies, issued on Wednesday and not separately repo...